Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine - PubMed (original) (raw)

Clinical Trial

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

C C Peeters et al. Vaccine. 1996 Jul.

Abstract

A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7h,4; P1.5c,10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 micrograms of the individual PorAs, was studied. The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA.

PubMed Disclaimer

Similar articles

• Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.
  van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, Claassen I, Poolman J. van der Voort ER, et al. Infect Immun. 1997 Dec;65(12):5184-90. doi: 10.1128/iai.65.12.5184-5190.1997. Infect Immun. 1997. PMID: 9393814 Free PMC article.
• Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
  van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J. van der Voort ER, et al. Infect Immun. 1996 Jul;64(7):2745-51. doi: 10.1128/iai.64.7.2745-2751.1996. Infect Immun. 1996. PMID: 8698504 Free PMC article. Clinical Trial.
• Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine.
  Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Martin SL, et al. Vaccine. 2000 May 22;18(23):2476-81. doi: 10.1016/s0264-410x(00)00047-5. Vaccine. 2000. PMID: 10775781 Clinical Trial.
• Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.
  de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, Juttmann R, Rümke HC. de Kleijn ED, et al. Vaccine. 2000 Feb 14;18(15):1456-66. doi: 10.1016/s0264-410x(99)00423-5. Vaccine. 2000. PMID: 10618543 Clinical Trial.
• Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
  Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, Gil A, Levie K, Kervyn AD, Weynants V, Dominguez F, Barberá R, Sotolongo F. Boutriau D, et al. Clin Vaccine Immunol. 2007 Jan;14(1):65-73. doi: 10.1128/CVI.00230-06. Epub 2006 Oct 25. Clin Vaccine Immunol. 2007. PMID: 17065257 Free PMC article. Clinical Trial.

Cited by

• Bactericidal Antibody Responses to Meningococcal Recombinant Outer Membrane Proteins.
  Zhu M, Sun Y. Zhu M, et al. J Microbiol Biotechnol. 2024 Jul 28;34(7):1419-1424. doi: 10.4014/jmb.2401.01018. Epub 2024 Apr 24. J Microbiol Biotechnol. 2024. PMID: 38955797 Free PMC article.
• Emerging role of microbiota derived outer membrane vesicles to preventive, therapeutic and diagnostic proposes.
  Jalalifar S, Morovati Khamsi H, Hosseini-Fard SR, Karampoor S, Bajelan B, Irajian G, Mirzaei R. Jalalifar S, et al. Infect Agent Cancer. 2023 Jan 19;18(1):3. doi: 10.1186/s13027-023-00480-4. Infect Agent Cancer. 2023. PMID: 36658631 Free PMC article. Review.
• Experimental Urethral Infection with Neisseria gonorrhoeae.
  Waltmann A, Duncan JA, Pier GB, Cywes-Bentley C, Cohen MS, Hobbs MM. Waltmann A, et al. Curr Top Microbiol Immunol. 2022 Mar 5:10.1007/82_2021_250. doi: 10.1007/82_2021_250. Online ahead of print. Curr Top Microbiol Immunol. 2022. PMID: 35246736 Free PMC article.
• Commensal and Pathogenic Bacterial-Derived Extracellular Vesicles in Host-Bacterial and Interbacterial Dialogues: Two Sides of the Same Coin.
  Tarashi S, Zamani MS, Omrani MD, Fateh A, Moshiri A, Saedisomeolia A, Siadat SD, Kubow S. Tarashi S, et al. J Immunol Res. 2022 Feb 17;2022:8092170. doi: 10.1155/2022/8092170. eCollection 2022. J Immunol Res. 2022. PMID: 35224113 Free PMC article. Review.
• Membrane Distribution of the Pseudomonas Quinolone Signal Modulates Outer Membrane Vesicle Production in Pseudomonas aeruginosa.
  Florez C, Raab JE, Cooke AC, Schertzer JW. Florez C, et al. mBio. 2017 Aug 8;8(4):e01034-17. doi: 10.1128/mBio.01034-17. mBio. 2017. PMID: 28790210 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information